Drugs / MR-107A-02
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05317312 | Mar → Jun 2022 | — | Mylan Specialty, LP | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06215820 | Dec 2023 → Aug 2024 | — | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 3 | NCT06215859 | Dec 2023 → Jan 2025 | — | Viatris Specialty LLC | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference viatris.com ↗ |
| 2025-05-08 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain viatris.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR-107A-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05317312 ↗ |
| Route | Oral | “MR-107A-02 oral tablet” NCT05317312 ↗ |